Skip to main content

Ysios Capital Partners leads €2M Series A Financing of STAT Diagnostica

By 16 de June de 2011November 18th, 2020No Comments
< Back to news

Ysios Capital Partners leads €2M Series A Financing of STAT Diagnostica

Ysios Capital Partners –base in teh Barcelona Scientific Park (PCB)–today announces that it has led a €2M Series A investment in STAT Diagnostica, another company based in the PCB. The venture fund from Instituto de Crédito Oficial (ICO) FESpyme FCR, managed by Axis Participaciones Empresariales, has joined the round.

STAT Diagnostica was founded in 2010, and is focused on the development of Point of Care solutions for clinical diagnostics with the objective of simplifying current procedures and reducing time to result. Proceeds from Series A will allow STAT Diagnostica to develop its in-vitro Point of Care diagnostics platform. This is a versatile, easy to use solution that can perform both molecular diagnostics and immunoassay. Its main applications will be in the fields of infectious diseases, antibiotic resistances and measuring biomarkers in critical patients or urgent situations.

STAT Diagnostica’s platform will enable multi analyte and multi sample detection as well as a significant reduction of time to result, in some cases from several days to one hour or even 15 minutes. This will help physicians to quickly determine appropriate treatments for the patients and it will have direct and indirect positive impact in cost for the health systems.

“The platform that we are developing will allow us to perform diagnostic tests close to the patient and to obtain results in a short period of time without the need to involve central laboratories. In addition, the simplicity of use, reliability and capacity to generate complementary analytical results, will be key to help the physician to determine appropriate treatments from the very beginning in patients at risk”, says Jordi Carrera, Managing Director and Co-Founder of STAT Diagnostica.

“STAT Diagnostica fits very well with our investment strategy. It is addressed to a medical need currently not properly solved and its implementation will represent a benefit for the patient and important savings for the health systems. It is expected that Point of Care diagnostics market will grow significantly in the coming years, and STAT’s platform gathers a number of competitive advantages over products in the market and in development. The 2 product profile and the experience and commitment of the founders, convinced us to invest in STAT Diagnostica”, says Raúl Martín-Ruiz, Investment Director of Ysios Capital Partners.